GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » Net Current Asset Value

Prenetics Global (Prenetics Global) Net Current Asset Value : $4.43 (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Prenetics Global's net current asset value per share for the quarter that ended in Sep. 2023 was $4.43.

The historical rank and industry rank for Prenetics Global's Net Current Asset Value or its related term are showing as below:

PRE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.95   Med: 1.64   Max: 2.61
Current: 1.08

During the past 4 years, the highest Price-to-Net-Current-Asset-Value Ratio of Prenetics Global was 2.61. The lowest was 0.95. And the median was 1.64.

PRE's Price-to-Net-Current-Asset-Value is ranked better than
90.77% of 130 companies
in the Medical Diagnostics & Research industry
Industry Median: 4.29 vs PRE: 1.08

Prenetics Global Net Current Asset Value Historical Data

The historical data trend for Prenetics Global's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global Net Current Asset Value Chart

Prenetics Global Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Current Asset Value
- -0.52 -59.80 18.26

Prenetics Global Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.71 18.26 15.17 12.40 4.43

Competitive Comparison of Prenetics Global's Net Current Asset Value

For the Diagnostics & Research subindustry, Prenetics Global's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prenetics Global's Price-to-Net-Current-Asset-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prenetics Global's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Prenetics Global's Price-to-Net-Current-Asset-Value falls into.



Prenetics Global Net Current Asset Value Calculation

Prenetics Global's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net Current Asset Value Per Share(A: Dec. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(241.81-68.668-6.399-0)/9.13221
=18.26

Prenetics Global's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2023 is calculated as

Net Current Asset Value Per Share(Q: Sep. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(105.187-47.63-4.349-0)/12.0181
=4.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prenetics Global  (NAS:PRE) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Prenetics Global Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Prenetics Global's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Prenetics Global (Prenetics Global) Business Description

Traded in Other Exchanges
N/A
Address
Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG
Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.